Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT

Biotech Will Need Cash To Finalize Pivotal Program

 
• By Mandy Jackson

Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.

Schizophrenia and split personality disorder and mental health psychiatric disease concept
Reviva plans to also develop its drug for bipolar disorder, depression and ADHD • Source: Shutterstock

More from Clinical Trials

More from R&D